All In Biotech

Drug Trial Radar · NCT05607680

A Study of IBI362 in Participants With Obesity or Overweight

A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

610

Actual

Start

Nov 14, 2022

Primary completion

Aug 21, 2023

Study completion Apr 16, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Conditions

  • Obesity Or Overweight

Interventions

  • PlaceboDrug

    Placebo administered subcutaneously (SC) once a week.

  • IBI362Drug

    IBI362 administered subcutaneously (SC) once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body WeightTime frame: Baseline, Week 32
  2. Percentage of Participants who Achieve ≥5% Body Weight ReductionTime frame: Week 32

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Xuancheng People's Hospital

    Xuancheng, Anhui, China

  • People's Hospital of Peking University

    Beijing, Beijing Municipality, China

  • Luoyang Third People's Hospital

    Luoyang, He'nan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, He'nan, China

  • The First Affiliated Hospital of Nanyang Medical University

    Nanyang, He'nan, China

  • The Third Affiliated Hospital of Xinxiang Medical University

    Xinxiang, He'nan, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • The First People's Hospital Of Kunshan

    Kunshan, Jiangsu, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Affiliated Hospital Of Nantong University

    Nantong, Jiangsu, China

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • China-Japan Union Hospital of Jilin University

    Changchun, Jilin, China

  • Shenyang Fifth People's Hospital

    Shenyang, Liaoning, China

  • Jinan Central Hospital

    Ji'nan, Shandong, China

  • Shandong Provincial Third Hospital

    Ji'nan, Shandong, China

  • Qilu Hospital Of Shandong University (Qingdao)

    Qingdao, Shandong, China

  • Tai'an Central Hospital

    Tai’an, Shandong, China

  • Zibo Municipal Hospital

    Zibo, Shandong, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Yan'an University Xianyang Hospital

    Xianyang, Shanxi, China

  • Huzhou Central Hospital

    Huzhou, Zhejiang, China

  • Lishui Central Hospital

    Lishui, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.